Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

XLMTM

- PMLiVE

Ipragliflozin beats diabetes rivals to Japanese approval

Astellas drug is first SGLT2 inhibitor backed by country’s regulator

- PMLiVE

Astellas boosts vaccine ambitions

Forms alliance with ClearPath Development

- PMLiVE

Astellas taps Lilly for comms chief

Jeffrey Winton appointed first chief communications officer

- PMLiVE

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

- PMLiVE

Astellas wins EU approval for prostate cancer drug Xtandi

Will compete with J&J’s big-selling Zytiga

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

FDA turns down tivozanib for kidney cancer

Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable"

- PMLiVE

Interview: Kay Drake and Naoki Okamura, Astellas

Astellas’ vice president of marketing, Europe and its chief strategy officer, Europe discuss category leadership, the changing landscape of market access and growth in a time of austerity

- PMLiVE

Regulatory struggles force Aveo to cut 140 jobs

Expects FDA rejection for tivozanib in kidney cancer

- PMLiVE

Orphan status in US for Astellas/ Basilea antifungal

Isavuconazole is being developed as a treatment for invasive aspergillosis

- PMLiVE

Amgen boosts Japan prospects with Astellas partnership

Companies establish joint venture and plan to co-develop new medicines

- PMLiVE

Astellas gets first OK for prostate drug Vesomni

Approved in the Netherlands to treat men with lower urinary tract symptoms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links